GlobeNewswire Inc.··Serina TherapeuticsSerina Therapeutics Advances SER-252 Development With First Phase 1b Enrollee
Serina Therapeutics enrolls first patient in Phase 1b trial for SER-252, an apomorphine-based Parkinson's treatment. FDA alignment on regulatory pathway supports streamlined development timeline.
SERFDA clearancePhase 1b trial